New trends in the management of leukemia

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Robin Foà, MD, from Sapienza University, Rome, Italy, summarises major advances, including the development of immunotherapy and targeted therapies, in the treatment of patients with hematological malignancies. Discussed examples include the introduction of B-cell receptor (BCR) kinase inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML).